Alisertib plus VCR plus pan-PI3K inhibition significantly reduced the expression of PD-L1 and NF-κβ, which are key drivers PTCL proliferation. Here, NFKB1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.